Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study

SIMPLE SUMMARY: Chemoimmunotherapy improved overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC) in two phase III trials, which set the age-stratified subgroup analyses at 65 years. Considering the super-aged society of Japan, tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Takayuki, Yamada, Tadaaki, Kunimatsu, Yusuke, Tanimura, Keiko, Morimoto, Kenji, Shiotsu, Shinsuke, Chihara, Yusuke, Okada, Asuka, Horiuchi, Shigeto, Hibino, Makoto, Uryu, Kiyoaki, Honda, Ryoichi, Yamanaka, Yuta, Yoshioka, Hiroshige, Kurata, Takayasu, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001399/
https://www.ncbi.nlm.nih.gov/pubmed/36900334
http://dx.doi.org/10.3390/cancers15051543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001399/
https://www.ncbi.nlm.nih.gov/pubmed/36900334
http://dx.doi.org/10.3390/cancers15051543

Ejemplares similares